Total Company Net Revenue Increased 40% versus Prior Year to Reach an All-Time High of $156.5 Million
Record Level Profitability with Net Income of $25.7 Million, Full-Year EBITDA Margin of 26% and Operating Cash Generation of $25 Million
Conference Call and Webcast Scheduled for 8:30 AM EST Today
RALEIGH, N.C., March 10, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. BDSI, a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the fourth quarter and full-year ended December 31, 2020, as well as the following operational and performance highlights.
Key Business Highlights
- Total Company full-year net revenue of $156.5 million delivered growth of 40% versus 2019 mainly driven by BELBUCA® (buprenorphine buccal film) CIII net sales of $136.1 million, an increase of 40% compared to 2019, and Symproic® (naldemedine) net sales of $14.7 million in 2020, an increase of 83% over 2019.
- Total Company net revenue for the fourth quarter increased by 33% versus the prior year period to $42.2 million. This growth was driven by BELBUCA net sales of $35.6 million, an increase of 26% versus the prior year period, and Symproic net sales of $3.7 million, an increase of 35% compared to the fourth quarter of 2019.
- BELBUCA reached all-time high prescription volume and market share, with total BELBUCA prescriptions of close to 119,000 during the fourth quarter, representing year-over-year prescription volume growth of 21%.
- Symproic reached all-time high prescription volume and market share, with total Symproic prescriptions of close to 19,000 in the fourth quarter, representing growth of 10% versus the prior year.
- Achieved significant profitability delivering $10.2 million of GAAP Net Income and an attractive 34% EBITDA margin in the fourth quarter of 2020, as well as full year GAAP net income of $25.7 million, or $0.26 per share, and a 26% EBITDA margin.
- The Company initiated share repurchases late in the fourth quarter under the previously announced share buyback program, completing purchases of 48,000 shares in the fourth quarter, and approximately 660,000 additional share purchases in the first quarter through March 8th, for approximately $2.9 million in total.
- Terry Coelho promoted to Executive Vice President and Chief Financial Officer.
"The impressive momentum and growth of our innovative products has persisted through the fourth quarter and full year 2020. Our high performing commercial team has been responding effectively to the evolving market conditions during the pandemic, and focused execution during the fourth quarter drove strong prescription trends for both BELBUCA and Symproic," stated Jeff Bailey, CEO of BDSI. "Our brands continued to capture market share in 2020 and the Company is poised for continued success as the selling environment improves in 2021."
Fourth Quarter 2020 Financial Results
Total Company Net Revenue for the fourth quarter of 2020 was a record $42.2 million, an increase of 33% compared to $31.6 million in the fourth quarter of 2019, and an increase of 7% compared to $39.4 million in the third quarter of 2020.
BELBUCA Net Sales for the fourth quarter of 2020 were $35.6 million, an increase of 26% compared to $28.3 million in the fourth quarter of 2019, and an increase of 2% compared to $34.8 million in the third quarter of 2020. BELBUCA gross to net deductions increased in the fourth quarter as anticipated, primarily due to typical increases seen for Medicare coverage gap.
Symproic Net Sales for the fourth quarter were $3.7 million, an increase of 35% compared to $2.7 million in the fourth quarter of 2019, and an increase of 6% compared to $3.5 million in the third quarter of 2020.
BUNAVAIL Net Revenue for the fourth quarter was $2.4 million, reflecting the release of a portion of the sales returns reserves taken at the time discontinuation was announced. In June 2020, the Company discontinued marketing of BUNAVAIL.
Total Operating Expenses for the fourth quarter of 2020 were $21.4 million, compared to $23.8 million in the fourth quarter of 2019 and $22.5 million in the third quarter of 2020.
GAAP Net Income for the fourth quarter of 2020 was $10.2 million, or $0.10 per share, compared to GAAP net loss of $0.7 million, or $0.01 per share, in the fourth quarter of 2019 and GAAP net income of $9.4 million, or $0.09 per share, in the third quarter of 2020.
EBITDA for the fourth quarter of 2020 was $14.3 million, or 34% of net sales, compared to $4.1 million or 13% of net sales, in the fourth quarter of 2019.
Non-GAAP Net Income for the fourth quarter of 2020 was $13.7 million and reflects GAAP net income excluding stock-based compensation and non-cash amortization of intangible assets. This reflects an increase of $7.3 million as compared to non-GAAP net income of $6.4 million in the fourth quarter of 2019, excluding the same items plus the non-recurring financial impact of discontinuation of the marketing of BUNAVAIL.
Full-Year 2020 Financial Results
Total Net Revenue for full-year 2020 was $156.5 million, an increase of 40% compared to $111.4 million for full-year 2019.
BELBUCA Net Sales for full-year 2020 were $136.1 million, an increase of 40% compared to $97.5 million for full-year 2019.
Symproic Net Sales for full-year 2020 were $14.7 million, an increase of 83% compared to 2019. The Company acquired Symproic in April 2019 and generated net sales of $8.1 million during the period from April to December 2019.
BUNAVAIL Net Revenue for full-year 2020 was $3.7 million, compared to $2.3 million for full-year 2019, and includes the release of certain sales returns reserves of $2.4 million following the discontinuation of marketing in June 2020.
Product Royalty Revenue for full-year 2020 was $1.9 million, compared to $3.5 million for full-year 2019.
Total Operating Expenses for full-year 2020 were $98.8 million, compared to $86.1 million for full-year 2019.
GAAP Net Income for full-year 2020 was $25.7 million, or $0.26 per share, an increase of $41.0 million compared to GAAP net loss of $15.3 million, or $(0.18) per share, for full-year 2019.
EBITDA for full-year 2020 was $40.5 million, or 26% of net sales, an increase of $28.0 million compared to $12.5 million, or 11% of net sales for full-year 2019.
Non-GAAP Net Income for full-year 2020 was $44.2 million and reflects GAAP net income excluding stock-based compensation, non-cash amortization of intangible assets, one-time expenses related to the CEO transition were incurred in 2020, and the non-recurring financial impact related to the discontinuation of the marketing of BUNAVAIL.
Cash Position: As of December 31, 2020, cash and cash equivalents were approximately $111.6 million, compared to $63.9 million as of December 31, 2019. The total cash flow generation over 2020 of $47.7 million includes operating cash generation of $25 million, $3.4 million in proceeds from the exercise of options, and net proceeds of $19.6 million from the draw down in May 2020 of $20 million from our existing debt facility, partially offset by $0.2 million used to repurchase shares in the quarter.
Financial Guidance
The Company expects full year 2021 total net sales of $170 - $180 million, including full year 2021 BELBUCA net sales of $155 - $165 million. These estimates incorporate the expected impact in Q1 2021 from the winter storms in the South-Central region, which affected some of the Company's most productive territories. Total operating expenses are expected to be in the range of $115 - $120 million, as the Company continues to invest to support the growth of its brands, and EBITDA is expected to be in the range of $40 - $50 million in 2021. The Company expects to continue being operating cash flow positive throughout 2021.
"I'm proud of how the BDSI team really pulled together, and also thrived, during 2020 in what was a challenging year for the industry due to the pandemic. I would like to recognize the efforts and contributions of all BDSI employees. I have great confidence that, with the strength of this team, high-growth brands, and a strong balance sheet, BDSI will continue to drive long-term shareholder value," stated Jeff Bailey.
Conference Call & Webcast Details
BioDelivery Sciences will host a conference call and webcast today, March 10, 2021, at 8:30 a.m. ET to present fourth quarter and full-year 2020 results and to provide a business update. Dial-in details are as follows:
| Date: | Wednesday, March 10, 2021 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13715530 |
| Webcast: | http://public.viavid.com/index.php?id=143193 |
ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.
BioDelivery Sciences International, Inc. BDSI is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. ("BDSI") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of BDSI's management and are subject to significant risks and uncertainties, including those detailed in BDSI's filings with the Securities and Exchange Commission. Actual results (including, without limitation, the expectations for total company net sales, BELBUCA net sales, operating expenses, EBITDA and operating cash flows in 2021) may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI's control) including the risk that the current coronavirus pandemic impacts on our supply chain, commercial partners, patients and their physicians and the healthcare facilities in which they work, and our personnel are greater than we anticipate, as well as those set forth in our 2019 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP, including non-GAAP net income and EBITDA. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net income adjusts for one-time and non-cash charges by excluding the following from GAAP net income: stock-based compensation expense, non-cash amortization of intangible assets, amortization of certain warrant discount costs, and the financial impact of certain one-time items that are non-recurring, including the financial impact of the debt refinancing in 2019, the discontinuation of marketing of BUNAVAIL, and costs associated with the CEO transition in 2020.
EBITDA excludes net interest, including both interest expenses and interest income, provision for (benefit from) income taxes, depreciation and amortization.
The Company's management and board of directors utilize these non-GAAP financial measures to evaluate the Company's performance. The Company provides these non-GAAP measures of the Company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income and EBITDA are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income and EBITDA should not be considered measures of our liquidity.
A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
© 2021 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
| December 31, 2020 | December 31, 2019 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 111,584 | $ | 63,888 | |||
| Accounts receivable, net | 48,150 | 38,790 | |||||
| Inventory, net | 17,443 | 11,312 | |||||
| Prepaid expenses and other current assets | 5,208 | 3,769 | |||||
| Total current assets | 182,385 | 117,759 | |||||
| Property and equipment, net | 1,418 | 2,075 | |||||
| Goodwill | 2,715 | 2,715 | |||||
| License and distribution rights, net | 53,376 | 60,309 | |||||
| Other intangible assets, net | — | 47 | |||||
| Total assets | $ | 239,894 | $ | 182,905 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued liabilities | $ | 52,995 | $ | 53,993 | |||
| Total current liabilities | 52,995 | 53,993 | |||||
| Notes payable, net | 78,452 | 58,568 | |||||
| Other long-term liabilities | 213 | 580 | |||||
| Total liabilities | 131,660 | 113,141 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred Stock, 5,000,000 shares authorized; 2,714,300 shares issued; Series A Non-Voting Convertible Preferred Stock. $0.001 par value, 0 and 2,093,155 shares outstanding at December 31, 2020 and December 31, 2019, respectively; Series B Non-Voting Convertible Preferred Stock, $0.001 par value, 443 and 618 shares outstanding at December 31, 2020 and December 31, 2019 respectively. | — | 2 | |||||
| Common Stock, $.001 par value; 235,000,000 and 175,000,000 shares authorized at December 31, 2020 and December 31, 2019 respectively; 101,417,441 and 96,189,074 shares issued; 101,354,447 and 96,173,583 shares outstanding at December 31, 2020 and December 31, 2019, respectively. | 104 | 96 | |||||
| Additional paid-in capital | 449,264 | 436,306 | |||||
| Treasury stock, at cost, 62,994 and 15,491 shares as of December 31, 2020 and December 31, 2019, respectively | (252 | ) | (47 | ) | |||
| Accumulated deficit | (340,882 | ) | (366,593 | ) | |||
| Total stockholders' equity | 108,234 | 69,764 | |||||
| Total liabilities and stockholders' equity | $ | 239,894 | $ | 182,905 | |||
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. DOLLARS, IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS)
| Quarter Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2020 | 2019 | 2020 | 2019 | ||||||||||||
| Revenues: | |||||||||||||||
| Product sales | $ | 41,628 | $ | 30,450 | $ | 154,574 | $ | 107,888 | |||||||
| Product royalty revenues | 539 | 1,187 | 1,897 | 3,341 | |||||||||||
| Contract revenues | — | — | — | 160 | |||||||||||
| Total Revenues: | 42,167 | 31,637 | 156,471 | 111,389 | |||||||||||
| Cost of sales | 8,294 | 7,265 | 24,665 | 21,590 | |||||||||||
| Expenses: | |||||||||||||||
| Selling, general and administrative | 21,418 | 23,759 | 98,827 | 86,063 | |||||||||||
| Total Expenses: | 21,418 | 23,759 | 98,827 | 86,063 | |||||||||||
| Income from operations | 12,455 | 613 | 32,979 | 3,736 | |||||||||||
| Interest expense, net | (2,028 | ) | (1,308 | ) | (7,013 | ) | (19,040 | ) | |||||||
| Other (expense)/income, net | 3 | (1 | ) | (3 | ) | 4 | |||||||||
| Income/(loss) before income taxes | 10,430 | (696 | ) | 25,963 | (15,300 | ) | |||||||||
| Income tax benefit | (233 | ) | — | (252 | ) | (5 | ) | ||||||||
| Net income/(loss) | 10,197 | (696 | ) | 25,711 | (15,305 | ) | |||||||||
| Net income/(loss) attributable to common stockholders | $ | 10,197 | $ | (696 | ) | $ | 25,711 | $ | (15,305 | ) | |||||
| Basic | |||||||||||||||
| Weighted average common stock shares outstanding | 101,178,994 | 92,118,497 | 99,830,520 | 83,213,704 | |||||||||||
| Basic earnings/(loss) per share | $ | 0.10 | $ | (0.01 | ) | $ | 0.26 | $ | (0.18 | ) | |||||
| Diluted | |||||||||||||||
| Weighted average common stock shares outstanding | 105,648,727 | 92,118,497 | 105,062,522 | 83,213,704 | |||||||||||
| Diluted earnings/(loss) per share | $ | 0.10 | $ | (0.01 | ) | $ | 0.24 | $ | (0.18 | ) | |||||
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS
(U.S. DOLLARS, IN THOUSANDS)
| Year Ended December 31, | |||||||||||
| 2020 | 2019 | 2018 | |||||||||
| Operating activities: | |||||||||||
| Net income (loss) | $ | 25,711 | $ | (15,305 | ) | $ | (33,867 | ) | |||
| Adjustments to reconcile net income (loss) to net cash flows used in operating activities | |||||||||||
| Depreciation | 538 | 1,846 | 740 | ||||||||
| Accretion of debt discount and loan costs | 320 | 11,508 | 4,138 | ||||||||
| Amortization of intangible assets | 6,981 | 6,981 | 5,157 | ||||||||
| Provision for (recovery from) inventory obsolescence | 1,870 | 197 | (56 | ) | |||||||
| Impairment loss on equipment | — | — | 78 | ||||||||
| Stock-based compensation expense | 9,595 | 5,416 | 5,941 | ||||||||
| Deferred income taxes | — | — | 40 | ||||||||
| Changes in assets and liabilities, net of effect of acquisition: | |||||||||||
| Accounts receivable | (9,360 | ) | (25,163 | ) | (4,640 | ) | |||||
| Inventories | (8,001 | ) | (6,102 | ) | 741 | ||||||
| Prepaid expenses and other assets | (1,439 | ) | (581 | ) | 422 | ||||||
| Accounts payable and accrued expenses | (1,234 | ) | 32,275 | (2,807 | ) | ||||||
| Net cash flows used in operating activities | 24,981 | 11,072 | (24,113 | ) | |||||||
| Investing activities: | |||||||||||
| Product acquisitions | — | (30,685 | ) | (1,951 | ) | ||||||
| Acquisitions of equipment | (13 | ) | (79 | ) | (112 | ) | |||||
| Net cash flows used in investing activities | (13 | ) | (30,764 | ) | (2,063 | ) | |||||
| Financing activities: | |||||||||||
| Proceeds from exercise of stock options | 3,369 | 2,321 | 670 | ||||||||
| Proceeds from issuance of common stock, less underwriters fee discount | — | 48,000 | — | ||||||||
| Proceeds from issuance of Series B preferred stock | — | — | 50,000 | ||||||||
| Payment on note payable | — | (67,346 | ) | — | |||||||
| Proceeds from notes payable | 20,000 | 59,987 | — | ||||||||
| Equity finance costs | — | (410 | ) | (1,417 | ) | ||||||
| Payment of deferred financing fees | (436 | ) | — | (450 | ) | ||||||
| Loss on refinancing of former debt | — | (2,794 | ) | — | |||||||
| Payment on share repurchase | (205 | ) | — | — | |||||||
| Net cash flows from financing activities | 22,728 | 39,758 | 48,803 | ||||||||
| Net change in cash and cash equivalents | 47,696 | 20,066 | 22,627 | ||||||||
| Cash and cash equivalents at beginning of year | 63,888 | 43,822 | 21,195 | ||||||||
| Cash and cash equivalents at end of year | $ | 111,584 | $ | 63,888 | $ | 43,822 | |||||
BIODELIVERY SCIENCES INTERNATIONAL, INC. AND SUBSIDIARIES
UNAUDITED RECONCILIATION OF NON-GAAP METRICS
(U.S. DOLLARS, IN THOUSANDS)
| Year Ended December 31, | ||||||||||
| Reconciliation of GAAP net income/(loss) to EBITDA (non-GAAP) | 2020 | 2019 | 2018 | |||||||
| GAAP net income/(loss) | $ | 25,711 | $ | (15,305 | ) | $ | (33,867 | ) | ||
| Add back/(subtract): | ||||||||||
| Income tax provision | 252 | 5 | 14 | |||||||
| Net interest expense | 7,013 | 19,036 | 10,206 | |||||||
| Depreciation and amortization | 7,521 | 8,748 | 6,188 | |||||||
| EBITDA | $ | 40,497 | $ | 12,484 | $ | (17,459 | ) | |||
| Reconciliation of GAAP net income/(loss) to Non-GAAP net income/(loss) | ||||||||||
| GAAP net income/(loss) | 25,711 | (15,305 | ) | (33,867 | ) | |||||
| Non-GAAP adjustments: | ||||||||||
| Stock-based compensation expense | 6,107 | 5,416 | 5,941 | |||||||
| Amortization of intangible assets | 6,982 | 6,981 | 5,157 | |||||||
| Amortization of warrant discount | — | 448 | 1,076 | |||||||
| Non-recurring financial impact of debt refinance | — | 11,866 | — | |||||||
| Non-recurring financial impact of BUNAVAIL discontinuation | 295 | 3,750 | — | |||||||
| Non-recurring financial impact of CEO transition | 5,145 | — | — | |||||||
| Non-GAAP net income/(loss) | $ | 44,240 | $ | 13,156 | $ | (21,693 | ) | |||
| Quarter Ended, | ||||||||||
| Reconciliation of GAAP net income/(loss) to EBITDA (non-GAAP) | December 31, 2020 | September 30, 2020 | December 31, 2019 | |||||||
| GAAP net income/(loss) | $ | 10,197 | $ | 9,383 | $ | (696 | ) | |||
| Add back: | ||||||||||
| Provision for income taxes | 233 | 211 | 1 | |||||||
| Net interest expense | 2,022 | 2,012 | 1,308 | |||||||
| Depreciation and amortization | 1,806 | 1,754 | 3,491 | |||||||
| EBITDA | $ | 14,258 | $ | 13,360 | $ | 4,104 | ||||
| Reconciliation of GAAP net income/(loss) to Non-GAAP net income/(loss) | ||||||||||
| GAAP net income/(loss) | 10,197 | 9,383 | (696 | ) | ||||||
| Non-GAAP adjustments: | ||||||||||
| Stock-based compensation expense | 1,750 | 1,473 | 1,438 | |||||||
| Amortization of intangible assets | 1,733 | 1,734 | 1,899 | |||||||
| Non-recurring financial impact of BUNAVAIL discontinuation | — | — | 3,750 | |||||||
| Non-recurring financial impact of CEO transition | — | 67 | — | |||||||
| Non-GAAP net income | $ | 13,680 | $ | 12,657 | $ | 6,391 | ||||
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
